374 related articles for article (PubMed ID: 33739848)
1. Comparison of Radiation With or Without Concurrent Trastuzumab for HER2-Positive Ductal Carcinoma In Situ Resected by Lumpectomy: A Phase III Clinical Trial.
Cobleigh MA; Anderson SJ; Siziopikou KP; Arthur DW; Rabinovitch R; Julian TB; Parda DS; Seaward SA; Carter DL; Lyons JA; Dillmon MS; Magrinat GC; Kavadi VS; Zibelli AM; Tiriveedhi L; Hill ML; Melnik MK; Beriwal S; Mamounas EP; Wolmark N
J Clin Oncol; 2021 Jul; 39(21):2367-2374. PubMed ID: 33739848
[TBL] [Abstract][Full Text] [Related]
2. Long-term outcomes of invasive ipsilateral breast tumor recurrences after lumpectomy in NSABP B-17 and B-24 randomized clinical trials for DCIS.
Wapnir IL; Dignam JJ; Fisher B; Mamounas EP; Anderson SJ; Julian TB; Land SR; Margolese RG; Swain SM; Costantino JP; Wolmark N
J Natl Cancer Inst; 2011 Mar; 103(6):478-88. PubMed ID: 21398619
[TBL] [Abstract][Full Text] [Related]
3. Preliminary results of centralized HER2 testing in ductal carcinoma in situ (DCIS): NSABP B-43.
Siziopikou KP; Anderson SJ; Cobleigh MA; Julian TB; Arthur DW; Zheng P; Mamounas EP; Pajon ER; Behrens RJ; Eakle JF; Leasure NC; Atkins JN; Polikoff JA; Seay TE; McCaskill-Stevens WJ; Rabinovitch R; Costantino JP; Wolmark N
Breast Cancer Res Treat; 2013 Nov; 142(2):415-21. PubMed ID: 24202240
[TBL] [Abstract][Full Text] [Related]
4. Prognostic Factors for Local Control in Breast Cancer After Long-term Follow-up in the EORTC Boost vs No Boost Trial: A Randomized Clinical Trial.
Vrieling C; van Werkhoven E; Maingon P; Poortmans P; Weltens C; Fourquet A; Schinagl D; Oei B; Rodenhuis CC; Horiot JC; Struikmans H; Van Limbergen E; Kirova Y; Elkhuizen P; Bongartz R; Miralbell R; Morgan DA; Dubois JB; Remouchamps V; Mirimanoff RO; Hart G; Collette S; Collette L; Bartelink H;
JAMA Oncol; 2017 Jan; 3(1):42-48. PubMed ID: 27607734
[TBL] [Abstract][Full Text] [Related]
5. Factors associated with local recurrence and cause-specific survival in patients with ductal carcinoma in situ of the breast treated with breast-conserving therapy or mastectomy.
Vargas C; Kestin L; Go N; Krauss D; Chen P; Goldstein N; Martinez A; Vicini FA
Int J Radiat Oncol Biol Phys; 2005 Dec; 63(5):1514-21. PubMed ID: 16005576
[TBL] [Abstract][Full Text] [Related]
6. Association of Radiotherapy Boost for Ductal Carcinoma In Situ With Local Control After Whole-Breast Radiotherapy.
Moran MS; Zhao Y; Ma S; Kirova Y; Fourquet A; Chen P; Hoffman K; Hunt K; Wong J; Halasz LM; Freedman G; Prosnitz R; Yassa M; Nguyen DHA; Hijal T; Haffty BG; Wai ES; Truong PT
JAMA Oncol; 2017 Aug; 3(8):1060-1068. PubMed ID: 28358936
[TBL] [Abstract][Full Text] [Related]
7. Tamoxifen, radiation therapy, or both for prevention of ipsilateral breast tumor recurrence after lumpectomy in women with invasive breast cancers of one centimeter or less.
Fisher B; Bryant J; Dignam JJ; Wickerham DL; Mamounas EP; Fisher ER; Margolese RG; Nesbitt L; Paik S; Pisansky TM; Wolmark N;
J Clin Oncol; 2002 Oct; 20(20):4141-9. PubMed ID: 12377957
[TBL] [Abstract][Full Text] [Related]
8. Delay in radiotherapy is associated with an increased risk of disease recurrence in women with ductal carcinoma in situ.
Shurell E; Olcese C; Patil S; McCormick B; Van Zee KJ; Pilewskie ML
Cancer; 2018 Jan; 124(1):46-54. PubMed ID: 28960259
[TBL] [Abstract][Full Text] [Related]
9. Radiotherapy versus low-dose tamoxifen following breast-conserving surgery for low-risk and estrogen receptor-positive breast ductal carcinoma in situ: an international open-label randomized non-inferiority trial (TBCC-ARO DCIS Trial).
Kuo SH; Tseng LM; Chen ST; Sagara Y; Chang YC; Yeh HT; Kuo YL; Hung CC; Lu TP; Lee YH; Toi M; Huang CS
BMC Cancer; 2023 Sep; 23(1):865. PubMed ID: 37710198
[TBL] [Abstract][Full Text] [Related]
10. Adjuvant radiation therapy in small ductal carcinoma in situ.
Cho WK; Choi DH; Kim H; Noh JM; Park W; Cha H
Breast; 2019 Feb; 43():55-58. PubMed ID: 30448710
[TBL] [Abstract][Full Text] [Related]
11. Five year outcome of 145 patients with ductal carcinoma in situ (DCIS) after accelerated breast radiotherapy.
Ciervide R; Dhage S; Guth A; Shapiro RL; Axelrod DM; Roses DF; Formenti SC
Int J Radiat Oncol Biol Phys; 2012 Jun; 83(2):e159-64. PubMed ID: 22579378
[TBL] [Abstract][Full Text] [Related]
12. The influence of margin width and volume of disease near margin on benefit of radiation therapy for women with DCIS treated with breast-conserving therapy.
Rudloff U; Brogi E; Reiner AS; Goldberg JI; Brockway JP; Wynveen CA; McCormick B; Patil S; Van Zee KJ
Ann Surg; 2010 Apr; 251(4):583-91. PubMed ID: 20224381
[TBL] [Abstract][Full Text] [Related]
13. Adjuvant tamoxifen reduces subsequent breast cancer in women with estrogen receptor-positive ductal carcinoma in situ: a study based on NSABP protocol B-24.
Allred DC; Anderson SJ; Paik S; Wickerham DL; Nagtegaal ID; Swain SM; Mamounas EP; Julian TB; Geyer CE; Costantino JP; Land SR; Wolmark N
J Clin Oncol; 2012 Apr; 30(12):1268-73. PubMed ID: 22393101
[TBL] [Abstract][Full Text] [Related]
14. Prognostic Significance of Clinicopathologic Features in Patients With Breast Ductal Carcinoma-in-Situ Who Received Breast-Conserving Surgery.
Kuo SH; Lo C; Chen YH; Lien HC; Kuo WH; Wang MY; Lee YH; Huang CS
Clin Breast Cancer; 2018 Dec; 18(6):441-450.e2. PubMed ID: 29709458
[TBL] [Abstract][Full Text] [Related]
15. Significance of boost radiotherapy in early invasive ductal breast cancer with ductal carcinoma in situ component under negative surgical margins.
Shimizu N; Myojin M; Tamura M; Nishiyama N; Yamashiro K; Yuyama Y; Okazaki Y; Suzuki Y; Takahashi M
J Radiat Res; 2022 Jan; 63(1):80-87. PubMed ID: 34718690
[TBL] [Abstract][Full Text] [Related]
16. Local treatment options for young women with ductal carcinoma in situ: A systematic review and meta-analysis comparing breast conserving surgery with or without adjuvant radiotherapy, and mastectomy.
Chien JC; Liu WS; Huang WT; Shih LC; Liu WC; Chen YC; Chou KJ; Shiue YL; Lin PC
Breast; 2022 Jun; 63():29-36. PubMed ID: 35299032
[TBL] [Abstract][Full Text] [Related]
17. Clinicopathological predictive factors for ipsilateral and contralateral events following initial surgery to treat ductal carcinoma in situ.
Tamura N; Tsuda H; Yoshida M; Hojo T; Akashi-Tanaka S; Kinoshita T; Sugihara K
Breast Cancer; 2016 May; 23(3):510-8. PubMed ID: 25666939
[TBL] [Abstract][Full Text] [Related]
18. Breast-conserving treatment with or without radiotherapy in ductal carcinoma-in-situ: ten-year results of European Organisation for Research and Treatment of Cancer randomized phase III trial 10853--a study by the EORTC Breast Cancer Cooperative Group and EORTC Radiotherapy Group.
; ; Bijker N; Meijnen P; Peterse JL; Bogaerts J; Van Hoorebeeck I; Julien JP; Gennaro M; Rouanet P; Avril A; Fentiman IS; Bartelink H; Rutgers EJ
J Clin Oncol; 2006 Jul; 24(21):3381-7. PubMed ID: 16801628
[TBL] [Abstract][Full Text] [Related]
19. Comparison of ipsilateral breast tumor recurrence after breast-conserving surgery between ductal carcinoma in situ and invasive breast cancer.
Choi YJ; Shin YD; Song YJ
World J Surg Oncol; 2016 Apr; 14():126. PubMed ID: 27122132
[TBL] [Abstract][Full Text] [Related]
20. Association of Radiotherapy With Survival in Women Treated for Ductal Carcinoma In Situ With Lumpectomy or Mastectomy.
Giannakeas V; Sopik V; Narod SA
JAMA Netw Open; 2018 Aug; 1(4):e181100. PubMed ID: 30646103
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
